Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

ConclusionThe results of the BELIS study support that trastuzumab SC can be safely administered at home by a HCP and all patients considered this setting as beneficial. HCPs consider the SC formulation as the quickest method to administer trastuzumab.Trial registrationEudraCT Identifier: 2013-000123-13. ClinicalTrials.gov Identifier: NCT01926886.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research